As coronavirus vaccines and treatments advance rapidly through research and development, the world starts to consider what drugs and digital tools might be needed in the ‘new normal’.
The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes could become an option for earlier-stage COVID-19 outsi
The de-prioritisation of face-to-face interactions between patients and healthcare professionals in the wake of COVID-19's current emergency has motivated a lot of changes in healthcare sys
Health tech companies Aetion and Cegedim have agreed to combine their data platforms together, to allow clients to gauge how their therapies are performing in the real world.
The AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential drug that researchers hope could alter the course of the pande
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.